Search Results - "rituximab"

Refine Results
  1. 1
    Use of rituximab in systemic lupus erythematosus in children: a review

    Use of rituximab in systemic lupus erythematosus in children: a review by A. N. Arefyeva

    Published 2019-11-01

    Juvenile-onset  systemic lupus erythematosus (SLE) is a significant and urgent problem in the practice of pediatricians and rheumatologists  in both verifying its diagnosis and choosing treatment policies, by taking into account the features of the onset, the types of the disease course, and the hig...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy

    Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy by A. S. Avdeeva, M. V. Cherkasova, E. L. Nasonov

    Published 2021-09-01

    Objective. To study the relationship between the level of calprotectin (CP) and RA activity, the level of acute phase reactants, proinflammatory cytokines, chemokines and growth factors, to assess its dynamics during rituximab (RTM) biosimilar therapy.Material and methods. 20 patients with RA were e...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma

    Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma by Odd Terje Brustugun, Erik Waage Nielsen

    Published 2025-07-01 Subjects: Get full text
    Article

    Save to List
    Saved in:
  4. 4
    Pénfigo vulgar grave: reporte de caso de tratamiento exitoso con plasmaféresis y rituximab

    Pénfigo vulgar grave: reporte de caso de tratamiento exitoso con plasmaféresis y rituximab by Claudia Marcela Gaviria, Lina María Colmenares

    Published 2019-08-01

    Las enfermedades ampollosas autoinmunitarias se clasifican, según la profundidad de las ampollas en la piel, en intraepidérmicas (grupo de los pénfigos) y subepidérmicas (grupo de los penfigoides). En el grupo de los pénfigos hay seis variantes principales y el pénfigo vulgar es el más común de est...

    Full description

    Subjects: “…Pénfigo, rituximab, plasmaféresis.…”
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS

    USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS by Anna Vasilyevna Torgashina, S K Solovyev, E N Aleksandrova, S G Radenska-Lopovok, E L Nasonov

    Published 2010-08-01

    Objective: To evaluate the impact of rituximab (RTM) therapy on the clinical, morphological, and immunological parameters of lupus nephritis (LN) activity. Subjects and methods. The study included 19 patients with types III and IV LN (WHO classification) with its 6-133-month history. Their mean age...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  6. 6
    EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS

    EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS by Mikhail Sergeyevich Protopopov, I G Salikhov’, S P Yakupova, S A Lapshina, L I Myasoutova, R Z Abdrakipov, Sh F Erdes

    Published 2013-02-01

    Objective: to analyze the efficacy of rituximab (RTM) in patients with active ankylosing spondylitis (AS) resistant to conventional therapy. Subjects and methods. The trial enrolled 10 male patients with the reliable and valid diagnosis of AS who received therapy with RTM used in cases of steadily h...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

    Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy by Marco Allinovi, Maxime Teisseyre, Matteo Accinno, Cecilia Finocchi, Vincent L.M. Esnault, Marion Cremoni, Tommaso Mazzierli, Daniela Lazzarini, Micaela Anna Casiraghi, Céline Fernandez, Kévin Zorzi, Vesna Brglez, Lorenzo Cosmi, Andrea Matucci, Leonardo Caroti, Giulia Antognoli, Calogero Lino Cirami, Alessandra Vultaggio, Barbara Seitz-Polski

    Published 2025-08-01

    Introduction: Rituximab is a first-line treatment for primary membranous nephropathy (pMN), with proven efficacy and safety. The use of monoclonal antibodies such as rituximab can lead to the formation of antidrug antibodies that may interfere with the therapeutic response. In pMN, anti-rituximab an...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  8. 8
    EXPERIENCE OF RITUXIMAB TREATMENT IN A PATIENT WITH JUVENILE SCLERODERMA

    EXPERIENCE OF RITUXIMAB TREATMENT IN A PATIENT WITH JUVENILE SCLERODERMA by E. I. Alexeeva, S. I. Valieva, T. M. Bzarova, K. B. Isaeva, R. V. Denisova, T. V. Sleptsova, E. V. Mitenko

    Published 2012-05-01

    A clinical case of severe juvenile scleroderma is represented in this article. The patient had a high activity and aggressive course of disease, he was resistant to steroid, cyclophosphomide and methotrexate therapy in combination with drugs, improving blood circulation. The authors describe the suc...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Pénfigo eritematoso severo asociado a falla cutánea tratado exitosamente con rituximab

    Pénfigo eritematoso severo asociado a falla cutánea tratado exitosamente con rituximab by Bruny Carolina Llamas Castellanos, Iván Pérez-Háded, Laura C. García-Medina, Juliana Criales-Laguado

    Published 2024-07-01

    El pénfigo eritematoso (PE) es un subtipo clínico del grupo de enfermedades ampollosas pénfigo foliáceo. Enfermedad autoinmune infrecuente mediada por autoanticuerpos en contra de la desmogleína 1. Tiene un amplio espectro, que en casos severos puede presentarse compromiso multiorgánico. A la fecha...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  10. 10
    The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis

    The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis by L. P. Ananyeva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoytova, O. A. Koneva, O. B. Ovsyannikova, S. I. Glukhova, E. L. Nasonov

    Published 2023-08-01

    Introduction. The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a diseasemodifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One e...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  11. 11
    The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)

    The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study) by M. A. Korolev, Yu. B. Ubshaeva, N. Y. Banshchikova, E. A. Letyagina, A. A. Mullagaliev

    Published 2021-01-01

    Wide usage of biologic disease-modifying anti-rheumatic drugs (DMARDs) biosimilars in clinical practice has greatly increased the availability of biologic therapy for rheumatic patients. Nevertheless, not only economic expediency but efficacy and safety are the key principals of any treatment includ...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  12. 12
    Low Dose Vs Conventional Rituximab Regimen in Pemphigus Vulgaris – A Retrospective Single Centre Comparative Analysis to Assess the Clinical Efficacy and Cost-Effectiveness

    Low Dose Vs Conventional Rituximab Regimen in Pemphigus Vulgaris – A Retrospective Single Centre Comparative Analysis to Assess the Clinical Efficacy and Cost-Effectiveness by Amuthavalli Kanagarajan, Reena Rai, Shanmugasekar Chandrasekaran, Mahadevan Krishnaswamy, Bharathi Sivakumar

    Published 2025-07-01

    Background: Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), a B-cell-mediated autoimmune bullous disease. However, no clear consensus on the optimum dosage has been achieved yet. Objectives: To compare the clinical efficiency and cost-effectiveness of a low-dose (...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  13. 13
    THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)

    THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY) by E. L. Nasonov, E. V. Zonova, O. N. Ivanova, L. A. Knyazeva, V. I. Mazurov, R. R. Samigullina, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, A. E. Sizikov, D. G. Krechikova, N. A. Petrochenkova, Yu. S. Shapovalova, N. S. Soroka, S. I. Pimanov, A. M. Pristrom, E. V. Kunder, E. V. Chernyaeva, A. V. Eremeeva, R. Ivanov

    Published 2016-12-01

    The article considers the results of an international multicenter randomized clinical trial of the efficacy and safety of the brand-name drug rituximab (MabThera), a monoclonal antibody against CD20 antigen of B cells, and its biosimi-lar drug (Acellbia®) (the BIORA study) in patients with rheumatoi...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  14. 14
    Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice

    Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice by E. L. Nasonov, T. V. Popkova, A. M. Lila

    Published 2021-09-01

    Currently, strong evidence has been obtained for the fundamental role of pathological activation of B cells in the pathogenesis of immunoinflammatory (autoimmune) rheumatic diseases (IMRD), and drugs that specifically modulate the function or cause depletion of various subpopulations of B cells and...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  15. 15
    TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT

    TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT by A V Bezgin, L A Knyazeva

    Published 2011-08-01

    Objective: to study the time course of rituximab therapy-induced changes in the synovial fluid levels of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), interleukins (IL) 1β and 6, and tumor necrosis factor-α (TNF-α) in patients with rheumatoid arthritis (RA). Res...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  16. 16
    Combined chemoimmunotherapy of patients with mature B-cell non-Hodgkin lymphomas age group until 18 years: results of multicenter study NHL 2004 m with rituximab and modified B-NHL BFM 90 protocol applications

    Combined chemoimmunotherapy of patients with mature B-cell non-Hodgkin lymphomas age group until 18 years: results of multicenter study NHL 2004 m with rituximab and modified B-NHL... by E. V. Samochatova, L. N. Schelikhova, M. B. Belogurova, A. V. Schamardina, E. V. Bascharova, D. V. Litvinov, N. V. Myakova, L. G. Fechina, O. P. Chlebnikova, E. V. Inuschkina, O. V. Riskal, P. Z. Schammasov, I. M. Yunusova, S. Yu. Umnova, D. M. Konovalov, A. G. Talalaev, J. V. Roumiantseva, A. A. Maschan

    Published 2022-11-01

    Therapy results of 61 patients (children and adolescents, 2—17 years of age; a median — 8.76 years) with B-cells non-Hodgkin lymphomas III—IV stage and B-cell acute leukemia (B-NHL/B-ALL), treating according to protocol with polichemotherapy and monoclonal antibodies against B-cell receptor CD20 — r...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  17. 17
    Safety and tolerability of rituximab in the treatment of systemic sclerosis

    Safety and tolerability of rituximab in the treatment of systemic sclerosis by L. A. Garzanova, L. P. Ananyeva, O. A. Koneva, O. V. Desinova, M. N. Starovoytova, O. B. Ovsyannikova, R. U. Shayakhmetova, S. I. Glukhova

    Published 2023-04-01

    Introduction. Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and interstitial lung disease. However, data on tolerability and long-term adverse events (AEs) during RTX therapy in SSc are insufficient.Objective...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  18. 18
    THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL

    THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL by E. L. Nasonov, V. I. Mazurov, E. V. Zonova, L. A. Knyazeva, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, Yu. S. Shapovalova, E. P. Ilivanova, D. G. Krechikova, N. A. Petrochenkova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, A. F. Davydova, N. A. Eremina, E. V. Zemerova, T. B. Ivanova, A. A. Kastanayan, T. G. Pokrovskaya, S. A. Smakotina, E. A. Smolyarchuk, A. V. Artemyeva, R. A. Ivanov, Yu. V. Usacheva, E. V. Chernyaeva

    Published 2017-09-01

    The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is a biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there has been evidence that RTM can be used at lower doses than th...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  19. 19
    Experience in Rituximab Administration in Children with Systemic Lupus Erythematosus: a Retrospective Study of the Case Series

    Experience in Rituximab Administration in Children with Systemic Lupus Erythematosus: a Retrospective Study of the Case Series by Mikhail M. Kostik, Ekaterina M. Kuchinskaya, Farida N. Abduragimova, Olga P. Gurina, Olga V. Kalashnikova, Vyacheslav G. Chasnyk

    Published 2016-08-01

    Systemic lupus erythematosus (SLE) in children has unpredictable and severe course. There is currently no standard therapy for the treatment of the disease. The article presents the results of a retrospective study of rituximab efficiency in 16 children with SLE aged 5 to 16 years who were hospitali...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  20. 20
    Evaluation of the Efficiency of Treatment with Rituximab for Systemic Scleroderma (A Case Report)

    Evaluation of the Efficiency of Treatment with Rituximab for Systemic Scleroderma (A Case Report) by E. N. Harlamova, Ju. Ju. Karpenko

    Published 2021-01-01

    The article describes a clinical case of a progressive form of systemic scleroderma in a 39-year-old man. The patient has an acute course and rapid progression of the disease with a significant initial decrease in the forced vital capacity of the lungs, with signs of an unfavorable prognosis, such a...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:

Search Tools: